LENZ Therapeutics GAAP EPS of -$1.16 misses by $0.26, revenue of $1.59M misses by $1.5M [Seeking Alpha]
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: Seeking Alpha
Cash, cash equivalents and marketable securities were $292.3 million as of December 31, 2025, which is anticipated to fund operations to post-launch positive operating cash flow. Fresh Stock Ideas, Every Day More on LENZ Therapeutics Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag Seeking Alpha's Quant Rating on LENZ Therapeutics Historical earnings data for LENZ Therapeutics Financial information for LENZ Therapeutics Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswire
- LENZ Therapeutics (LENZ) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LENZ&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holdMarketBeat
- LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026GlobeNewswire
- LENZ Therapeutics (LENZ) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of PresbyopiaGlobeNewswire
LENZ
Earnings
- 3/24/26 - Miss
LENZ
Sec Filings
- 3/24/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/5/26 - Form SCHEDULE
- LENZ's page on the SEC website